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Previously, we have shown that copy number gain of the chromosomal
band 16q24.3 is associated with impaired clinical outcome of radiotherapy-
treated head and neck squamous cell carcinoma (HNSCC) patients. We set
out to identify a prognostic mRNA signature from genes located on
16q24.3 in radio(chemo)therapy-treated HNSCC patients of the TCGA
(The Cancer Genome Atlas, n = 99) cohort. We applied stepwise forward
selection using expression data of 41 16q24.3 genes. The resulting optimal
Cox-proportional hazards regression model included the genes APRT,
CENPBD1, CHMP1A, and GALNS. Afterward, the prognostic value of
the classifier was confirmed in an independent cohort of HNSCC patients
treated by adjuvant radio(chemo)therapy (LMU-KKG cohort). The signa-
ture significantly differentiated high- and low-risk patients with regard to
overall survival (HR = 2.01, 95% CI 1.10–3.70; P = 0.02125), recurrence-
free survival (HR = 1.84, 95% CI 1.01–3.34; P = 0.04206), and locore-
gional recurrence-free survival (HR = 1.87, 95% CI 1.03–3.40;
P = 0.03641). The functional impact of the four signature genes was inves-
tigated after reconstruction of a gene association network from transcrip-
tome data of the TCGA HNSCC cohort using a partial correlation
Abbreviations
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CHMP1A, charged multivesicular body protein 1A; CI, confidence interval; FDR, false discovery rate; FFPE, formalin-fixed paraffin-
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doi:10.1002/1878-0261.12388 approach. Subsequent pathway enrichment analysis of the network neigh-
borhood (first and second) of the signature genes suggests involvement of
HNSCC-associated signaling pathways such as apoptosis, cell cycle, cell
adhesion, EGFR, JAK-STAT, and mTOR. Furthermore, a detailed analy-
sis of the first neighborhood revealed a cluster of co-expressed genes
located on chromosome 16q, substantiating the impact of 16q24.3 alter-
ations in poor clinical outcome of HNSCC. The reported gene expression
signature represents a prognostic marker in HNSCC patients following
postoperative radio(chemo)therapy.
1. Introduction
Head and neck squamous cell carcinoma (HNSCC)
comprises a group of heterogeneous tumors from dif-
ferent anatomical sites with tobacco smoking and alco-
hol abuse as the major risk factors (Marcu and Yeoh,
2009). Infection with high-risk human papillomavirus
(HPV) is another emerging risk factor. HPV-related
tumors are characterized by a distinct molecular
pathogenesis with a considerably favorable prognosis
(Leemans et al., 2011; O’Sullivan et al., 2013). Despite
advances in treatment modalities, the 5-year survival
rate for advanced HNSCC still needs improvement.
The identification of patients with therapy-resistant
tumors using prognostic markers would allow person-
alized treatment approaches (Mirghani et al., 2015;
O’Sullivan et al., 2013); however, such markers are not
yet established.
So far, research groups have mainly focused on the
identification of single molecular markers to be used
for diagnosis and treatment selection in HNSCC
(Rocco et al., 2006). Due to the complexity and
heterogeneity of tumors, it is likely that instead of a
single gene, the prognostic value of a gene signature
with regard to patient outcome would be more power-
ful (Ginos et al., 2004; Lohavanichbutr et al., 2013;
Pavon et al., 2012). Up to now, mRNA expression sig-
natures associated with metastasis (Lian et al., 2013;
Roepman et al., 2006), hypoxia (Eustace et al., 2013;
Toustrup et al., 2012), HPV status (Cancer Genome
Atlas, 2015; Slebos et al., 2006), and immune response
(Chung et al., 2004; Wood et al., 2016) have been
reported in HNSCC. Although, for example, the
immune response signature of Chung et al. and the
hypoxia signatures developed by Eustace et al. and
Toustrup et al. could be confirmed in subsequent pub-
lications (Keck et al., 2015; Tawk et al., 2016), many
molecular signatures, some of them very complex, fail
independent validation and therefore to change prac-
tice in a clinical setting. This might be explained by
methodological aspects such as the selection and num-
ber of genes examined, differences in the analysis plat-
forms used, restrictions due to small sample sizes, lack
of independent validation, but also by demographic
differences in the patient groups examined or the
unavailability of detailed clinical information.
Previously, we demonstrated an association of gains
of chromosomal band 16q24.3 with locoregional pro-
gression-free survival of radiotherapy-treated HNSCC
patients (Bauer et al., 2008) and validated this marker
in the subgroup of adjuvant radio(chemo)therapy-trea-
ted patients of the TCGA HNSCC cohort (Hess et al.,
2017). Since copy number alterations might lead to
aberrant mRNA expression of genes (Gollin, 2014),
our objective was to develop a prognostic mRNA sig-
nature from genes located on this chromosomal band
using a stepwise forward selection approach. The prog-
nostic value of the gene classifier was analyzed in an
independent HNSCC cohort. In addition, the func-
tional role of the signature genes was investigated.
2. Methods
2.1. Patients
Our study was conducted in compliance with the
Reporting recommendations for tumor MARKer
prognostic studies (REMARK) (McShane et al., 2005)
and fulfills the requirements set out by Simon et al.
(2009), which are summarized in Table S1 (Simon
et al., 2009).
We analyzed two independent cohorts of HNSCC
patients who had undergone surgical resection fol-
lowed by adjuvant radio(chemo)therapy: the TCGA
and the LMU-KKG cohort (Ludwig-Maximilians-Uni-
versity of Munich, Clinical Cooperation Group ‘Per-
sonalized Radiotherapy in Head and Neck Cancer’)
(Maihoefer et al., 2018).
For the TCGA HNSCC cohort, mRNA expression
(RNA Seq V2 RSEM)-level z-scores of genes located
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on chromosomal band 16q24.3 (generated by the
TCGA Research Network http://cancergenome.nih.
gov) were downloaded from cBioPortal (2015/08/12)
(Cancer Genome Atlas, 2015; Cerami et al., 2012; Gao
et al., 2013). Inclusion criteria for patients of the
TCGA cohort were as follows: (a) Treatment with
radio(chemo)therapy; (b) no therapy in the frame of
neoadjuvant, recurrent, or palliative treatment; (c)
availability of HPV status; (d) availability of mRNA
expression and genomic copy number data of genes
located on chromosomal band 16q24.3. The resulting
patient subset of 99 radio(chemo)therapy-treated
HNSCC patients (Table S2) was randomly split into a
training (n = 40) and a validation set (n = 59) while
ensuring equal percentage distribution of HPV-positive
cases. Median follow-up times of the training and vali-
dation set were 656 and 643 days, respectively.
The retrospective LMU-KKG cohort served as an
independent validation cohort. This study on clinical
and biological data was approved by the local ethics
committee in Munich (EA 448-13 and 17-116) and car-
ried out in accordance with the Declaration of Hel-
sinki. The experiments were undertaken with the
understanding and written consent of each subject. The
LMU-KKG cohort included all patients with HNSCC
of the hypopharynx, larynx, oropharynx, or oral cavity
treated at the Department of Radiation Oncology,
LMU, Germany, between 2008 and 2013 (Maihoefer
et al., 2018). All patients received adjuvant radiother-
apy as a curative approach after surgical resection. The
median overall treatment time was 45 days (interquar-
tile range 43–47 days) with five fractions per week.
A median radiation dose of 64 Gy (2 Gy/fraction) was
applied to the former tumor bed or regions of ECE.
Elective lymph node regions have been covered accord-
ing to tumor stage and localization with a median dose
of 50 Gy (2 Gy/fraction) and 56 Gy (2 Gy/fraction)
were applied to involved lymph node regions. In the
case of close (R0, but less than 5 mm) or positive
microscopic resection margins and/or ECE, patients
received concurrent chemotherapy; 47.2% of the
patients received CDDP/5-fluorouracil (5-FU) (CDDP:
20 mgm2 days 1–5/29–33; 5-FU: 600 mgm2 days
1–5/29–33). In some cases, Mitomycin C (MMC)
(10.2%) or 5-FU/MMC (5.6%) was used instead of
platinum-based chemotherapy. End of follow-up period
was on 14 May 2016, and the median OS time was
1878 days. The clinical and pathological data for both
cohorts are presented in Table 1. A comparison of
demographic parameters between the TCGA and the
LMU-KKG cohort is given in Table S3.
Hemotoxylin and eosin (HE)-stained tissue sections
from available formalin-fixed and paraffin-embedded
(FFPE) tissue blocks were histopathologically reviewed
by a pathologist (A.W.), and the tumor containing
area was defined. Samples with < 50% tumor cells
were excluded from further analysis. Guided by the
HE-stained tissue slides, the annotated tumor area was
micro-dissected followed by simultaneous DNA and
RNA extraction using the AllPrep DNA/RNA FFPE
Kit (Qiagen, Hilden, Germany) according to the man-
ufacturer’s protocol. After DNA/RNA isolation and
quality assessment, 108 HNSCC samples remained for
further analysis.
2.2. Determination of the HPV status
HPV status of the patients was determined by p16INK4a
immunohistochemistry in combination with HPV
DNA detection. Immunohistochemical (IHC) p16INK4a
staining, used as a surrogate marker for HPV-infec-
tion, was performed using the CINtec TM Histology
Kit (Roche mtm Laboratories AG, Heidelberg, Ger-
many) on a Ventana Benchmark LT automated
immunostainer (Ventana Medical Systems, Tucson,
AZ, USA) according to the manufacturer’s protocol.
FFPE sections of embedded p16-positive (UPCI
SCC154) and p16-negative HNSCC cell lines (Cal33)
were included as positive and negative controls. Tumor
specimens with strong and diffuse nuclear and cyto-
plasmic staining in more than 70% of tumor cells were
considered as p16-positive, whereas tissues with only
faintly diffuse or absent staining were considered as
p16-negative (Ang et al., 2010). p16-stained tissue sec-
tions were evaluated by two independent observers
(L.W. and J.H.). Further, detection of mucosotropic
HPV DNA was performed using quantitative real-time
PCR (q-PCR) in combination with SYBR green chem-
istry (Clontech Laboratories, Inc., Mountain View,
CA, USA). DNA samples (50 ng) were subjected to q-
PCR products (10 lL) on a ViiA 7 q-PCR system
(Thermo Fisher Scientific, Dreieich, Germany) using
GP5+/6+ primers detecting the L1 gene (Eurofins
MWG Operon, Ebersberg, Germany) (forward primer:
50-TTTGTTACTGTGGTAGATACTAC-30, reverse
primer: 50-GAAAAATAAACTGTAAATCATATTC-30;
amplicon size: 142 bp) (Hesselink et al., 2005). The
b-globin gene served as quality control (forward primer:
50-CAGGTACGGCTGTCATCACTTAGA-30, reverse
primer: 50-CATGGTGTCTGTTTGAGGTTGCTA-30;
amplicon size: 185 bp) (Metabion International AG,
Planegg-Martinsried, Germany) (Lindh et al., 2007).
Two HPV-positive (UPCI SCC2 and UPCI SCC154)
and two HPV-negative (Cal27 and Cal33) cell lines were
included as controls. Reactions were carried out in tripli-
cates along with negative controls. Samples with a
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detectable b-globin PCR product (Ct-value < 35) were
considered as HPV-negative if no HPV amplification
product was detectable.
A tumor specimen was classified as HPV-positive if it
was positive for both p16INK4a IHC and HPV DNA sta-
tus assessed by GP 5+/6+ q-PCR (Smeets et al., 2007).
2.3. Development of a gene classifier
A schematic workflow for the development of the gene
classifier and the reconstruction of the gene association
network (GAN) with subsequent analyses is presented
in Fig. S1.
A prognostic gene classifier regarding OS was built
by applying a robust likelihood-based survival model-
ing approach on mRNA gene expression data
(z-scores) of the TCGA training set using the R-package
rbsurv (Cho et al., 2009). A stepwise forward selection
algorithm computed the partial likelihood of the Cox-
proportional hazards regression model for a sequential
selection of mRNA (100 iterations, twofold cross-valida-
tion), which allowed choosing the best performing
model based on the Akaike information criterion, an
estimator of the relative quality of a statistical model
considering the goodness of fit penalized by model com-
plexity, in terms of the best trade-off between minimum
complexity and best goodness of fit of the model.
Cox model coefficients [adenine phosphoribosyltrans-
ferase (APRT): 1.20988822, CENPBD1: 0.06012163,
CHMP1A: 0.17153750, GALNS: 0.22431583] were mul-
tiplied with the corresponding mRNA expression values
and summed up to an individual risk score for each
patient. For the determination of the cutoff for the indi-
vidual risk score stratifier, survival analyses were per-
formed in the TCGA training set with cutoff values
varying with increment of 0.1 starting from the minimal
risk score. The cutoff, which resulted in the optimal
split of patients in terms of log-rank test P-value (OS)
in the training set, was used for assorting each patient
individually into a low-risk (< 0.2932616) and a high-
risk group (≥ 0.2932616). Both the model and the cut-
off value derived from the TCGA training dataset were
applied to the expression data of the TCGA validation
set and the LMU-KKG cohort. Expression data for the
LMU-KKG cohort were gained from quantitative real-
time RT-PCR (qRT-PCR) analysis.
2.4. Quantitative real-time RT-PCR (qRT-PCR)
analysis of the signature genes in the LMU-KKG
cohort
For the LMU-KKG HNSCC cohort, mRNA expres-
sion of the signature genes was analyzed by qRT-
PCR. Reverse transcription was performed using the
SuperScript VILOTM cDNA Synthesis Kit (Life Tech-
nologies, Carlsbad, CA, USA) with 500 ng RNA
input. qRT-PCR products (10 lL) were carried out in
triplicates according to manufacturer’s protocol on an
Applied Biosystems ViiATM7 platform employing
the Taqman Assays (Life Technologies) APRT-
Hs00975725_m1, CHMP1A-Hs00946132_g1, CENP
BD1-Hs00924894_s1, and GALNS-Hs00975732_m1.
b-Actin (ACTB-Hs01060665_g1) and phosphoglycerate
kinase 1 (PGK1-Hs99999906_m1) served as endogenous
controls. Expression levels were determined using the
DCt method followed by z-score transformation.
2.5. Clinical endpoints LMU-KKG cohort
Clinical endpoints included OS, recurrence-free sur-
vival, and locoregional recurrence-free survival. OS
was calculated (in days) from the date of radiother-
apy treatment start to the date of death from any
cause. Recurrence-free survival was defined as the
time (days) from the start of radio(chemo)therapy
treatment to the first observation of locoregional/dis-
tant recurrence or death due to any cause; locore-
gional recurrence-free survival from the start of radio
(chemo)therapy treatment to the date of local recur-
rence or death due to any cause. In the absence of an
event, patients were censored at the date of the last
follow-up visit.
2.6. Genomic copy number data
File IDs of patients of the adjuvant radio(chemo)
therapy-treated TCGA HNSCC cohort were
extracted using the GDC web API. Genomic copy
number alterations SNP 6.0 raw data (.CEL files)
were downloaded from the GDC data portal
(https://portal.gdc.cancer.gov/). The CEL files were
batch processed using functions of the rawcopy R-
package (http://rawcopy.org). The normal tissue data
served as reference data to build normalized log2
intensity copy number ratios for each of the tumor
samples. The log2-ratios were segmented and the
copy number status determined using functions of
the R-package CGHcall (van de Wiel et al., 2007).
After determination of the DNA status, integration
analysis of copy number data with the transcriptome
data was carried out.
2.7. Statistical analysis
Comparisons of two Kaplan–Meier curves were per-
formed using the log-rank test of the R-package
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survival; P-values < 0.05 were considered statistically
significant. Median estimates and hazard ratios (HR)
with 95% confidence intervals (CI) were determined.
P-values were also calculated for the training set, but
since no valid null-hypothesis can be formulated in
this case, it only reflects the meaningful split of risk
groups. The association of clinical parameters with
clinical endpoints was assessed using univariate Cox-
proportional hazards regression analysis. Parameters
with P < 0.05 in univariate analysis were included into
a multivariate Cox-proportional hazards model.
Association of the copy number status of chromoso-
mal band 16q24.3 with risk scores or mRNA expres-
sion levels of the signature genes was evaluated using
unpaired two-sided Mann–Whitney U-test.
2.8. Gene association network (GAN)
reconstruction
Raw RNA sequencing data on 98 HNSCC cases of
the adjuvant radio(chemo)therapy-treated TCGA
HNSCC cohort were downloaded from the GDC data
portal (https://portal.gdc.cancer.gov/). The RNA
sequencing reads contained in the BAM files were rea-
ligned to the reference transcriptome (GRCH38/
Ensembel) and quantified as Transcripts Per Million
(TPM) using the tool Salmon (Patro et al., 2017). The
identification of differentially expressed genes between
the high-risk and low-risk group was carried out using
the R-package DEseq2, where genes with a cumulative
(over samples) TPM ≤ 5 were excluded and genes with
an adjusted P-value < 0.1 were considered statistically
significant (Love et al., 2014).
Differentially expressed genes were subsequently
subjected to GAN reconstruction using the method
implemented in the GeneNet R-package, which is
based on regularized dynamic partial correlation
(Opgen-Rhein and Strimmer, 2007). The edge proba-
bility cutoff of 0.99 was applied to obtain the resulting
undirected GAN.
2.9. Gene set enrichment analysis
Gene sets from the Reactome database for gene set
enrichment analysis (GSEA) were downloaded from
the Broad Institute Molecular Signatures Database.
GSEA was carried out in the preranked mode: All
genes of the data set were ranked according to the
log2 transformed fold changes (four-gene signature
high-risk versus low-risk group). GSEA tests for up-
or down-regulation of gene sets (pathways), while gene
sets with false discovery rate (FDR) < 0.05 were
considered statistically significant.
2.10. Pathway enrichment analysis
The Cytoscape Reactome Functional Interaction (FI)
plugin (version 3.5.1) was used to perform a network
clustering of the FI network consisting of genes from
the GANs first and second neighborhood of the four
signature genes (Shannon et al., 2003; Wu et al.,
2010). A pathway enrichment analysis was conducted
for modules including more than 100 genes. Pathways
containing less than 200 but more than 20 genes were
considered for pathway enrichment analysis. P-values
were determined by one-sided Fisher’s exact test. Ben-
jamini–Hochberg adjusted P-values (FDR) < 0.05 were
considered statistically significant and ranked accord-
ing to ascending FDRs.
2.11. Integration of copy number data with the
transcriptome data
In order to assess whether mRNA expressions were
explainable by genomic copy number alterations, an
integration analysis was carried out on 98 HNSCC
samples from the TCGA cohort. For this purpose, the
Gene wise cisTest implemented in the Bioconductor
sigaR R-package was used (van Wieringen and van de
Wiel, 2009; van Wieringen et al., 2012). Default values
provided by the package were applied during the dif-
ferent analysis steps for all parameters, except
nGenes = 500, which potentially improves the overall
power of the FDR procedure included in the cisEffect-
Tune function. Overall, this integrative analysis
assesses the effect of the genomic copy number status
of each gene on its mRNA expression level and pro-
vides a measure on how much of the mRNA expres-
sion is explained by its copy number status. The
results are based on a permutation approach, while
10 000 permutations were used. The resulted P-values
were adjusted for multiple testing with the Benjamini–
Hochberg method. Due to the nature of permutation
tests, the results vary upon repetition of the test but
stay stable with the respect to the drawn conclusions.
3. Results
The identified best performing prognostic model gener-
ated from mRNA expression data of 16q24.3 genes
(n = 41) included the four genes APRT, CENPBD1,
CHMP1A, and GALNS allowing to stratify HNSCC
patients with regard to OS. A 5.76-fold (95% CI 1.73–
19.17) increased risk for death was observed for high-
risk patients (9/16, 56% patients with events)
compared to the low-risk group (7/24, 29% patients
with events) of the TCGA training set (n = 40)
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(Fig. 1A). The robustness of the four-gene classifier
was confirmed in the TCGA validation set as high-risk
classified patients showed significantly reduced OS
rates (10/29, 34% patients with events; hazard ratio
(HR) 3.81, 95% CI 1.05–13.89; P = 0.02911; Fig. 1B)
compared to low-risk patients (3/30, 10% patients with
events).
The mRNA expression levels of all signature genes
were up-regulated in high-risk patients and correlated
positively with the defined risk groups (Fig. 1A,B,
lower panel).
The four-gene classifier was independently validated
in the LMU-KKG cohort (n = 108) as high-risk group
patients showed significantly impaired OS rates (29/55,
45% patients with events; HR 2.01, 95% CI 1.10–3.70;
P = 0.02125) compared to low-risk patients (17/53,
32% patients with events) (Fig. 2A). Moreover, the
risk groups significantly differed with regard to locore-
gional recurrence-free survival (HR = 1.87, 95% CI
1.03–3.40; P = 0.03641) and recurrence-free survival
rates (HR = 1.84, 95% CI 1.01–3.34; P = 0.04206;
Fig. 2B).
In order to assess whether the classifier was an inde-
pendent prognostic factor, associations of known clini-
copathological factors with the high- and low-risk
groups were tested. HPV status was associated with
the signature-defined risk groups of the TCGA train-
ing and validation set (Table 1). All other demo-
graphic parameters were equally distributed among the
risk groups in both TCGA subsets and the LMU-
KKG HNSCC cohort. Univariate Cox regression anal-
yses revealed a significant association of HPV status
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Fig. 1. Identification of a four-gene classifier predicting OS in the subgroup of radio(chemo)therapy-treated HNSCC patients of the TCGA
cohort. (A) Kaplan–Meier curves for the endpoint OS for patients stratified according to the four-gene classifier of the training (a) and
validation (b) set within the radio(chemo)therapy-treated TCGA HNSCC cohort. Survival curves are depicted for all cases (training set:
n = 40, validation set: n = 59) and for HPV-negative cases only (training set: n = 31, validation set: n = 47). P-values, median OS times, and
hazard ratios (HR) with 95% contingency intervals were obtained by Log-rank test and are indicated. (B) Heatmap of mRNA expression
levels (z-scores) of the four signature genes (top panel) arranged according to risk scores (bottom panel) for the training (a) and validation (b)
set within the TCGA HNSCC cohort. mRNA expression levels of all four signature genes were elevated in patients of the high-risk group.
The results are in whole based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov (Cancer Genome Atlas,
2015; Cerami et al., 2012; Gao et al., 2013). NE, not estimable.
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with OS in both cohorts, which was also reflected by
an improved OS of oropharyngeal tumors (n = 7; all
HPV-positive) compared to tumors of the oral cavity
in the TCGA sets (Table S4).
Due to the lack of the presence of HPV-positive
cases in the TCGA high-risk groups, it was unfeasible
to conduct a multivariate analysis. Instead, survival
analyses were carried out stratified to HPV-negative
patients demonstrating a trend toward worse survival
of high-risk patients despite small group sizes in the
TCGA subsets (Fig. 1). An additional survival analysis
performed in the pooled HPV-negative tumors of the
TCGA subsets (training and validation) demonstrated
a significant separation of the four-gene signature clas-
sified risk groups low-risk and high-risk (HR 2.60,
95% CI 1.08–6.26; P = 0.001444) (Fig. S2). Inclusion
of HPV status in a multivariate Cox-proportional haz-
ard model in the LMU-KKG cohort revealed a signifi-
cant contribution of the four-gene classifier and HPV
status to the prediction model (Table 2). The inclusion
of both parameters HPV status and the four-gene sig-
nature in the model was justified because there was
no significant association between them (Fisher’s
exact test P-value = 0.6406; Table 1). An additional
stratified model including an interaction term revealed
no significant interaction between the four-gene signa-
ture and HPV status (P = 0.73). However, due to the
low number of events in the group of HPV-positive
cases (4/23 events; 17% of patients), the results can-
not consider being meaningful. Instead, we performed
survival analyses considering HPV-negative cases only
(Fig. 2).
Next, we assessed the association of DNA gains of
16q24.3 with mRNA expression levels of the signature
genes and the four-gene classifier risk scores. In both
TCGA subsets, significantly higher (P < 0.05) risk
scores were observed for HNSCC cases with compared
to cases without DNA gains of 16q24.3, also when
stratified to HPV-negative patients (Fig. 3). This was
also the case on single gene level (Fig. S3).
To get insights into the biological functions of the
signature genes, a GSEA of gene expression data with
regard to the signature-defined high- versus low-risk
groups was performed. Twenty-nine significantly
(FDR < 0.05) up-regulated (Table S5) and 53 down-
regulated gene sets (Table S6), respectively, in the
high-risk group compared to the low-risk group were
identified. Several significantly up-regulated gene sets
were related to FGFR signaling. Further, we found
up-regulated gene sets associated with PI3K cascade,
PD1 signaling, and TCR signaling. Most of the down-
regulated gene sets were associated with the regulation
of cell cycle, apoptosis, and DNA damage response.
In addition, a GAN was reconstructed. The first
neighborhood (direct neighbors, n = 92) and second
neighborhood (neighbors of first neighbors, n = 2972)
of the four signature genes were extracted, including
the information on the correlation of genes (Tables S7
and S8). Interestingly, direct network connections for
three (APRT, CENPBD1, CHMP1A) of the four sig-
nature genes were observed, whereas an indirect con-
nection was detected for galactosamine (N-acetyl)-6-
sulfatase (GALNS) (Fig. 4). All 50% of first neighbor-
hood genes are localized on chromosome 16q, and a
significant overrepresentation of 16q genes was
observed within the first neighborhood compared to
the entire network (Fisher’s exact test P < 0.001).
Subsequent pathway enrichment analysis of genes
from the first and second neighborhoods of the four
signature genes revealed 493 significantly enriched
pathways (FDR < 0.05) (Table S9). The top 50 identi-
fied pathways ordered according to the smallest FDR
included mainly pathways associated with cell cycle,
apoptosis, cell adhesion, immune response, JAK-
STAT-signaling, signaling by SCF-KIT, EGFR,
ERBB, WNT, mTOR, and PIP3/AKT signaling.
Integration of copy number data and transcriptome
data revealed a significant association (FDR < 0.1) of
the genomic copy number status and the correspond-
ing mRNA expression for 2952 out of the 7755 genes
preselected for GAN reconstruction, including 64 out
of 92 first neighborhood signature genes.
This represents a significant enrichment of genes
within the first neighborhood with a significant associ-
ation of the DNA status and their mRNA expression
compared to the preselection (Fisher’s exact test
P < 0.001). Out of the 64 genes, 46 are located on
chromosome 16q and thereby show a significant over-
representation of 16q genes with significant copy-num-
ber-mRNA association compared to the preselection
(Table S10).
4. Discussion
Gains of chromosomal band 16q24.3 were repeatedly
shown to be associated with impaired clinical outcome
of HNSCC patients after radiotherapy (Bauer et al.,
2008; Hess et al., 2017). Here, we investigated the
impact of 16q24.3 on mRNA expression level with
regard to patients’ outcome following radio(chemo)
therapy. We succeeded in the discovery and validation
of a prognostic four-gene classifier, consisting of the
genes APRT, CENPBD1, CHMP1A, and GALNS
located on 16q24.3. In our opinion, the fact that the
signature works in both cohorts (TCGA and LMU-
KKG cohort) although exhibiting significant
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demographic differences underlines its robustness,
which is one of the most important features of clini-
cally applicable biomarkers.
Up to now, HPV status is the most valid and robust
prognostic marker in HNSCC, whereas HPV-positive
tumors are now widely regarded as a distinct clinical
entity with a different molecular pathogenesis
(O’Sullivan et al., 2016). This emphasizes the impor-
tance for excluding possible confounding effects of
HPV status and of other clinical and pathological
parameters in prognostic marker research. For this
reason, the independence from other clinical parame-
ters is a particular strength of the presented classifier
and allows statistically significant stratification of
patient risk groups in the subgroup of HPV-negative
HNSCC.
Smoking and alcohol abuse are established risk fac-
tors for HNSCC, also contributing to a high preva-
lence of multiple comorbidities (e.g., cardiovascular,
pulmonary, or hepatic diseases), which have a particu-
larly high impact on the OS of HNSCC patients
(Datema et al., 2010). Consideration of tumor-specific
clinical endpoints provides a more solid basis in prog-
nostic marker development for HNSCC. In this sense,
the four-gene classifier was also prognostic for locore-
gional recurrence-free survival and recurrence-free sur-
vival of HNSCC patients following adjuvant radio
(chemo)therapy substantiating its clinical value. These
results correspond to the previously reported associa-
tion of DNA gains of 16q24.3 with locoregional recur-
rence-free survival in HNSCC (Bauer et al., 2008). The
prognostic value of the signature was additionally
underlined by the significant correlation of DNA gains
16q24.3 with elevated mRNA expression levels of the
four classifier genes. This is important to note because
copy number alterations not necessarily lead to aber-
rant mRNA expression of genes (Gollin, 2014; Jarvi-
nen et al., 2006).
An association of genomic gains on 16q24.3 with
increased mRNA expression levels was previously also
observed for the DNA repair-related gene FancA,
located within this chromosomal band. Further, silenc-
ing of FancA expression in HNSCC cell lines with
genomic gains on 16q24.3 resulted in significantly
impaired clonogenic survival upon irradiation, whereas
overexpression of FancA conferred increased survival
(Hess et al., 2017). Interestingly, the FancA gene was
not included in the best performing model when devel-
oping a low-complexity prognostic mRNA expression
signature including 16q24.3 genes. In this regard, we
have indications from another project that specific
transcript isoforms of FancA are associated with
HNSCC patient prognosis.
The potential exploitation of the four-gene signature
as a novel therapeutic target is dependent on their bio-
logical functions and involved pathways. A first insight
into the possible functional role of the signature genes
was gained from the published literature, but only lit-
tle information on the genes in context with HNSCC
or even with cancer was available. CHMP1A (charged
multivesicular body protein 1A) is known to act as a
tumor suppressor in pancreatic (Li et al., 2008, 2009)
and renal cancer (You et al., 2012) by inhibition of
tumor cell proliferation. However, an up-regulation of
CHMP1A in HNSCC might also have a converse
effect as multifunctional roles were shown for several
tumor-associated genes (Radin and Patel, 2017). Fur-
thermore, CENPBD1 (CENPB DNA-binding domain
containing 1) plays a role in centromere formation and
could, therefore, also have an influence on the cell
Table 2. Multivariate Cox regression analysis of the four-gene classifier and HPV status with OS in the LMU-KKG HNSCC cohort.
Cohort Parameter No. of cases HR 95% CI HR P-value (univariate analysis) P-value
LMU-KKG Four-gene classifier
(high-risk vs low-risk)
55 vs 53 2.17 1.18-4.00 0.022 0.013
+
HPV status
(negative vs positive)
85 vs 23 4.04 1.44-11.30 0.0067 0.0078
Fig. 2. Validation of the extracted four-gene classifier in an independent HNSCC cohort. Kaplan–Meier curves for the endpoints overall (A),
locoregional recurrence-free and recurrence-free survival (B) for patients stratified according to the four-gene classifier of the adjuvant radio
(chemo)therapy-treated LMU-KKG HNSCC cohort. Survival curves are shown for all cases (left panel) and for the HPV-negative cases (right
panel). Hazard ratios and median survival times with 95% contingency intervals and P-values were calculated by Log-rank test. Heatmap of
mRNA expression levels of the four signature genes arranged according to risk scores (A, lower panel) for patients of the adjuvant radio
(chemo)therapy-treated LMU-KKG cohort. All genes show a tendency toward higher expression in patients of the high-risk group. NE, not
estimable.
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cycle. The enzyme APRT (adenine phosphoribosyl-
transferase) is involved in purine metabolism (Kama-
tani et al., 1984), and deficiency of the lysosomal
exohydrolase GALNS is associated with the autosomal
recessive disorder Mucopolysaccharidosis IV A (Hor-
witz and Dorfman, 1978; Matalon et al., 1974). So far,
APRT and GALNS have not been described in con-
nection with cancer or cancer-associated molecular
pathways. However, a GSEA and the investigation of
our reconstructed GAN revealed evidence for specific
involvement of the four signature genes in pathways
associated with poor clinical outcome and therapy
resistance in HNSCC: for example, the EGFR/PIP3K/
AKT/mTOR pathway, involved in numerous cancer-
related processes including cell cycle progression and
apoptosis, is frequently altered in HNSCC and linked
to therapeutic failure (Freudlsperger et al., 2011; Niehr
et al., 2018). The mTOR pathway leads to the activa-
tion of the DNA-repair machinery, thereby inducing
higher radioresistance of HNSCC cells (Bose et al.,
2013). Also the identified aberrant DNA damage
response could indicate the involvement of the four
signature genes in the radiation resistance of tumor
cells (Hosoya and Miyagawa, 2014). Moreover, cell
adhesion molecules like integrins are promising targets
to overcome therapeutic resistance of HNSCC cells,
especially in combination with radiation and simulta-
neous targeting of EGFR (Eke et al., 2015). Further
identified pathways included the JAK-STAT signaling,
regulating cell proliferation, cell survival, and angio-
genesis (Bose et al., 2013). In combination with aber-
rant Interleukin and GM-CSF signaling, this causes
markedly immune system evasion of tumors, limiting
the efficacy of conventional therapies (Bose et al., 2013;
Wu et al., 2015). Also the reactivation of developmental
processes initiated by stem cell factor (SCF)/KIT, and
Wnt signaling may play a role in the therapeutic
response of HNSCC tumor cells (Ischenko et al., 2008).
Taken together, the involvement of the four signature
genes in those pathways could explain the worse clinical
outcome of high-risk patients as defined by the four-
gene classifier. Whether the functionality of the signa-
ture is related to a radiation-resistant phenotype, which
is partly suggested by the signaling pathways discussed
above, or rather to tumor aggressiveness, must be inves-
tigated in future in vitro studies.
Moreover, since copy number alterations not neces-
sarily lead to aberrant mRNA expression of genes
(Gollin, 2014; Jarvinen et al., 2006), it was an impor-
tant finding for us that in the case of 16q, where the
signature genes are located, the gene expression levels
are significantly associated with the corresponding
DNA copy number status. It underlines the prognostic
value of the signature based on the previous study on
a DNA gain of 16q24.3 (Bauer et al., 2008; Hess et al.,
2017) and its association with compromised therapy
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Fig. 3. DNA gains of chromosomal band 16q24.3 are associated with increased risk scores in radio(chemo)therapy-treated patients of the
TCGA HNSCC training and validation set. Distribution of risk scores in all (left panel) and in HPV-negative (right panel) cases with gain and
without gain of the chromosomal band 16q24.3 in the training (all cases: n = 40, HPV-negative cases: n = 31) (A) and validation (all cases:
n = 59, HPV-negative cases: n = 47) (B) set within the subgroup of radio(chemo)therapy-treated HNSCC of the TCGA cohort. Patients with a
DNA gain of 16q24.3 had significantly higher risk scores compared to patients without a DNA gain of 16q24.3 (Mann–Whitney U-test). The
association remained after stratification to HPV-negative patients. The results are in whole based upon data generated by the TCGA
Research Network: http://cancergenome.nih.gov (Cancer Genome Atlas, 2015; Cerami et al., 2012; Gao et al., 2013).
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Fig. 4. First neighborhood of the four signature genes from the reconstructed GAN in the TCGA HNSCC cohort. First neighborhood network
of the four signature genes (red) extracted from the GAN. De novo network reconstruction was based on partial correlation of differentially
expressed genes between high-risk and low-risk group patients in the TCGA HNSCC cohort (n = 98) using the GeneNet method. Black lines
(edges) represent positive, and blue lines negative correlations (interactions) between genes. Dotted lines indicate the connection between
the first neighborhood genes of GALNS and the first neighborhood genes of the other three signature genes. Genes, apart from the four
signature genes, localized on 16q are colored in cyan.
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response. Furthermore, these results in combination
with the analysis of the reconstructed GAN indicate a
possible cluster of co-expressed genes on chromosome
16q, including the four signature genes, with an impact
on cancer-related processes in HNSCC. Such clusters of
co-expressed genes were previously described in the
published literature (Caron et al., 2001) and are known
to consist of genes involved in the same functional
pathways (Lee and Sonnhammer, 2003). Based on these
facts, the cluster of co-expressed genes on 16q could be
involved in poor clinical outcome of HNSCC.
5. Conclusion
In conclusion, our findings do not only provide a
prognostic tool for stratification of HNSCC patients
treated with adjuvant radio(chemo)therapy into groups
of favorable and poor prognosis independent of other
clinical parameters. They also might help identifying
targets for molecular therapies, since the four-gene sig-
nature seems to be part of a functional gene expression
cluster involved in HNSCC-associated pathways.
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Fig. S1. Schematic workflow for the development of
the classifier and the reconstruction of the gene associ-
ation network with subsequent analyses.
Fig. S2. Kaplan–Meier curves for the endpoint overall
survival for the pooled HPV-negative patients of the
radio(chemo)therapy-treated TCGA training and vali-
dation set stratified according to the four-gene classi-
fier.
Fig. S3. DNA gains of chromosomal band 16q24.3 are
associated with increased mRNA expression levels of
the signature genes in radio(chemo)therapy-treated
patients of the TCGA HNSCC cohort.
Table S1. REporting recommendations for tumour
MARKer prognostic studies (REMARK) according to
McShane et al. (2005).
Table S2. Patient subset of 99 radio(chemo)therapy-
treated HNSCC patients of the TCGA cohort.
Table S3. Differences of demographic and histopatho-
logical parameters between the TCGA cohort and the
LMU-KKG cohort.
Table S4. Univariate Cox regression analyses of clinico-
pathological parameters and the four-gene classifier
with overall survival in the TCGA HNSCC training
and validation set and the LMU-KKG HNSCC cohort.
Table S5. Gene set enrichment analysis (GSEA): Sig-
nificantly (FDR < 0.05) up-regulated sets of genes
between the four-gene signature high and low-risk
groups of the TCGA cohort.
Table S6. Gene set enrichment analysis (GSEA): Sig-
nificantly (FDR < 0.05) down-regulated sets of genes
between the four-gene signature high and low-risk
groups of the TCGA cohort.
Table S7. Correlation of the first neighborhood genes
of the reconstructed gene association network.
Table S8. Correlation of the second neighborhood
genes of the reconstructed gene association network.
Table S9. Significantly enriched pathways (FDR < 0.05)
of first and second neighborhood genes of the four sig-
nature genes from the reconstructed GAN.
Table S10. Significant results of the sigaR cis-test.
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